Showing 781-790 of 9143 results for "".
The Treatment Landscape for Children and Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37153/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, provides an overview of current therapeutic options for pediatric atopic dermatitis patients.Cutaneous Toxicities in Graft-versus-host Disease
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/cutaneous-toxicities-in-graft-versus-host-disease/33013/Meghan Heberton, MD, an assistant professor of dermatology at UT Southwestern Medical Center, talks about her presentation at Masterclasses in Dermatology on the latest updates on cutaneous toxicities in Graft-versus-host (GvHD) disease.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.Noah Worcester 2024: Dr. Cohen on Lasers
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-cohen-lasers/24578/Joel L. Cohen, MD, FAAD, summarizes his lecture on laser resurfacing and perioral rejuvenation at the 2024 Noah Worcester Dermatological Society meeting.Hilary Baldwin, MD: Perspective on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/hilary-baldwin-md-perspective-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24171/Neal Bhatia, MD, chief medical editor of Practical Dermatology® talks to Hilary E. Baldwin, MD about a new report from an independent laboratory that finds benzene can form at unacceptably high levels in both over-the-counter and prescription medications that contain benzoyl peroxide.First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.PDT: Patient Profiles for a Practice-changing Treatment
https://practicaldermatology.com/series/pdt-in-practice/pdt-patient-profiles-for-a-practice-changing-treatment/20186/Who's the ideal candidate for PDT? Other options, limitations? The advances in PDT both doctors and patients would like to see are described by Corey Hartman, MD, who shares his experiences and relates how PDT has improved his practice.Choosing the Right Resurfacing Treatment
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/choosing-the-right-resurfacing-treatment/20141/Joel L. Cohen, MD discusses how he assesses the area around the mouth to determine the best resurfacing treatment option. From fine lines and etching around the mouth to issues with pigmentation and redness, he says there are many options from low-downtime treatments to full-field erbium treatments.DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eDermWireTV: Cutera, Galderma Acne Treatments; Alma's TED; Diversity Initiatives
https://practicaldermatology.com/topics/practice-management/dermwiretv-cutera-galderma-acne-treatments-almas-ted-diversity-initiatives/20084/There are two new options for treating acne. Cutera introduces the AviClear acne device; Galderma launches Twyneo Cream. Joshua Zeichner, MD weighs in. Lady Dy, MD discusses Alma’s TED device, a non-invasive, non-traumatic option to address hair loss. New initiatives announced at or in conjunction w